Clinical Trials Arena on MSN
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
The 4TAZPower study will follow participants with Barth syndrome for 72 weeks to assess the efficacy and safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results